Shattuck Labs, Inc.

Good morning and welcome to the Shattuck Labs third quarter 2023 earnings conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. We'll now turn the call over to your host, Connor Richardson, Vice President of Investor Relations at Shattuck Labs. Connor, please go ahead.

Thank you, Operator.

Good morning, everyone, and welcome to the Shattuck Labs conference call regarding our third quarter 2023 financial results and recent business updates. The press release reporting our financial results was issued pre-market this morning and can be found on the investor relations section of our website, shattucklabs.com. During this morning's call, the Shattuck leadership team will provide a business overview of the third quarter of 2023, including clinical development updates. Speaking on today's call will be our chief executive officer and scientific co-founder, Dr. Taylor Schreiber, our chief medical officer, Dr. Lenny Pendi, and our chief financial officer, Mr. Andrew Neal. We will then open the call for questions following our prepared remarks. Before we begin, I would like to remind you that today's webcast contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve certain risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on these risks and uncertainties, please refer to our most recent quarterly report on Form 10-Q for the quarter ended September 30, 2023 and our other filings with the SEC, which are available from the SEC's website or on our corporate website, ShattuckLabs.com. Any forward-looking statements represent our views as of today, November 9, 2023. With that, I will now turn the call over to Dr. Schreiber, our Chief Executive Officer. Taylor?